Letter: Anticoagulants in Venous Thrombosis,a Pivotal Risk Factor: Authors’ Reply

Abstract

Get full access to this article

View all access options for this article.

References

Siang Kow

Tiruchelvam

. Letter: Anticoagulants in venous thrombosis A pivotal risk factor. Angiology. 2024;75:899.

Soudet

Basille

Carette

Mercier

Andrejak

Sevestre

. Cardiovascular and venous thromboembolic events after hospital discharge for COVID-19: a prospective single center study. Angiology. 2024;75:893-898.

Danzi

Loffi

Galeazzi

Gherbesi

. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.

Zuily

Lefèvre

Sanchez

, et al. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine. 2023;60:102031.

ATTACC Investigators ACTIV-4a Investigators REMAP-CAP Investigators, Lawler

Goligher

Berger

. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med. 2021;385:790-802.

Ramacciotti

Barile Agati

Calderaro

, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399:50-9.

Zhou

, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.

Gaddh

Scott

Wysokinski

, et al. Comparison of venous thromboembolism outcomes after COVID-19 and influenza vaccinations. TH Open. 2023;7:e303-8.